|List |< first << previous [record 30 of 74] next >> last >||
|Institutional Source||Beutler Lab|
|Synonyms||PIP, beta-MSP, beta-inhibin, PSP94, prostatic inhibin protein|
|Is this an essential gene?||Non essential (E-score: 0.000)|
|Stock #||R1942 (G1)|
|Chromosomal Location||32142023-32158370 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||A to G at 32148077 bp|
|Amino Acid Change||Glutamic Acid to Glycine at position 2 (E2G)|
|Ref Sequence||ENSEMBL: ENSMUSP00000022464 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000022464] [ENSMUST00000130397]|
|Predicted Effect||probably benign
AA Change: E2G
PolyPhen 2 Score 0.004 (Sensitivity: 0.98; Specificity: 0.59)
AA Change: E2G
|Predicted Effect||noncoding transcript
|Meta Mutation Damage Score||0.0898|
|Coding Region Coverage||
|Validation Efficiency||100% (75/75)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] The protein encoded by this gene is a member of the immunoglobulin binding factor family. It is synthesized by the epithelial cells of the prostate gland and secreted into the seminal plasma. This protein has inhibin-like activity. It may have a role as an autocrine paracrine factor in uterine, breast and other female reproductive tissues. The expression of the encoded protein is found to be decreased in prostate cancer. Two alternatively spliced transcript variants encoding different isoforms are described for this gene. The use of alternate polyadenylation sites has been found for this gene. [provided by RefSeq, Jul 2008]
PHENOTYPE: Mice homozygous for a knock-in allele exhibit early prostate cancer development progressing from intraepithelial neoplasia with microinvasion to well-differentiated prostate gland adenocarcinoma, and show enlargement of the prostate gland and the lymph nodes, and increased metastatic potential. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Msmb||
(F):5'- GCCTCTTTACAAACCTTCCTAAGATTT -3'
(R):5'- CTAGGTCCTATCTACAGTTTGTATCT -3'
(F):5'- CAGTGAGTGCTCTTAACCACTGAG -3'
(R):5'- GTATCTACCAGGCTGGAATCG -3'